Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan

NCT07169708 is registered in ClinicalTrials.gov with Ono Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07169708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07169708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Phase
Observational
Overall status
Recruiting
Start date
March 20, 2026
Completion date
June 30, 2026
Enrollment
100 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer nsclc